I 
117TH CONGRESS 
1ST SESSION H. R. 6047 
To direct the Secretary of Health and Human Services to submit to Congress 
a report on COVID–19 natural immunity, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
NOVEMBER 18, 2021 
Mr. ROY (for himself, Mr. MASSIE, Mr. PERRY, Mr. ROSENDALE, Mrs. 
BOEBERT, Ms. STEFANIK, Mr. WEBER of Texas, and Mr. GOHMERT) in-
troduced the following bill; which was referred to the Committee on En-
ergy and Commerce 
A BILL 
To direct the Secretary of Health and Human Services to 
submit to Congress a report on COVID–19 natural im-
munity, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Natural Immunity 
4
Transparency Act’’. 
5
SEC. 2. REPORT ON COVID–19 NATURAL IMMUNITY. 
6
(a) IN GENERAL.—Not later than 30 days after the 
7
date of the enactment of this Act, the Secretary of Health 
8
VerDate Sep 11 2014 
05:08 Dec 04, 2021
Jkt 029200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H6047.IH
H6047
kjohnson on DSK79L0C42PROD with BILLS
2 
•HR 6047 IH
and Human Services shall submit to Congress a report 
1
that contains the following data— 
2
(1) the number of individuals who recovered 
3
from a COVID–19 infection, and never received a 
4
COVID–19 vaccine, during the period beginning on 
5
January 1, 2020, and ending on such date of enact-
6
ment, and who subsequently— 
7
(A) died from a COVID–19 infection; 
8
(B) were hospitalized from a COVID–19 
9
infection; 
10
(C) had an additional confirmed case of 
11
COVID–19; or 
12
(D) transmitted SARS–CoV–2 to another 
13
person or persons while reinfected; and 
14
(2) the number of individuals who received all 
15
recommended doses of a COVID–19 vaccine during 
16
the period beginning on December 14, 2020, and 
17
ending on such date of enactment, and who subse-
18
quently— 
19
(A) died from a COVID–19 infection; 
20
(B) were hospitalized from a COVID–19 
21
infection; or 
22
(C) had a confirmed breakthrough case. 
23
(b) DEFINITIONS.— In this section: 
24
VerDate Sep 11 2014 
05:08 Dec 04, 2021
Jkt 029200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H6047.IH
H6047
kjohnson on DSK79L0C42PROD with BILLS
3 
•HR 6047 IH
(1) BREAKTHROUGH CASE.—The term ‘‘break-
1
through case’’, with respect to a case of COVID–19, 
2
means the detection of SARS–CoV–2 RNA or anti-
3
gen in a respiratory specimen collected from an indi-
4
vidual at least 14 days after the date on which such 
5
individual received all recommended doses of a 
6
COVID–19 vaccine. 
7
(2) COVID–19 VACCINE.—The term ‘‘COVID– 
8
19 vaccine’’ means a vaccine for COVID–19 that 
9
has been licensed under section 351 of the Public 
10
Health Service Act (42 U.S.C. 262) or authorized 
11
for emergency use under section 564 of the Federal 
12
Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb– 
13
3). 
14
Æ 
VerDate Sep 11 2014 
05:08 Dec 04, 2021
Jkt 029200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6301
E:\BILLS\H6047.IH
H6047
kjohnson on DSK79L0C42PROD with BILLS
